GT Biopharma, Inc.
Close on Oct 19, 2026
- Market cap
- $259.71M
- P/E (TTM)
- –
- Dividend yield
- –
About GT Biopharma
Pharmaceutical Preparations, SIC 2834
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel immuno-oncology products. Its therapies utilize proprietary Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) fusion protein platforms. These therapeutics harness and enhance the cancer-killing capabilities of a patient's own natural killer cells to target hematologic malignancies, solid tumors, and viral infections. The company's candidate pipeline includes GTB-3550 and next-generation candidates such as GTB-3650, which target specific tumor antigens like CD33. Its therapeutics are intended for cancer patients as monotherapies or in combination with standard care.
The company operates as a fully remote organization without maintaining physical principal executive offices, receiving corporate correspondence in San Francisco, California. Its developmental operations rely on collaborations, scientific contractors, and academic partnerships, including work originated with the Masonic Cancer Center at the University of Minnesota in the United States.
Summary of the business section of GT Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- GT Biopharma, Inc.
- Founded
- 1965
- Headquarters
- San Francisco, CA
- Address
- 505 Montgomery Street, 10th Floor 94111
- Phone
- (800) 304-9888
- Website
- gtbiopharma.com
- Employees
- 1, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company, P.A, Los Angeles, California
Stock & identifiers
- Ticker
- GTBP
- Exchange
- Nasdaq
- Shares outstanding
- 45M, Aug 10, 2026
- Public float
- $8.60M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-25 reverse, Sep 8, 2026; 1-for-30 reverse, Mar 26, 2024; 1-for-30 reverse, Feb 5, 2024; 1-for-17 reverse, Feb 11, 2021; 1-for-250 reverse, Mar 30, 2016
- SEC CIK
- 109657
- CUSIP
- 36254L407
- ISIN
- US36254L4077
- LEI
- 549300HMPDDS7IM47Y18
- EIN
- 94-1620407
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michael Martin Breen | CEO and Director | 856,218 |
| Alan Louis Urban | Chief Financial Officer | – |
| Charles J. Casamento | Director | – |
| Hilary Kramer | Director | – |
| David C. Mun-Gavin | Director | – |
| Andrew J. Ritter | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Breen | $1.73M | $1.61M | $739.31K | $3 | – |
| FY2024 Mr. Breen | $1.19M | $1.19M | $377.78K | $3 | – |
| FY2023 Mr. Breen | $1.53M | $1.26M | $1.13M | $8 | – |
| FY2022 Mr. Breen | $1.89M | $1.50M | $944.54K | $28 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“At the date of this Annual Report, we have one full-time employee and numerous consultants to carry on our operations.”
Corporate history
Events identified from SEC filings